Home > What we do > Medicine & Healthcare > hMedicine > hMedicine Story

Hadassah’s Prof. Orly Elpeleg Receives KKL-JNF 2013 Outstanding Medical Scientist Award

Prof. Orly Elpeleg with Hadassah Medical Center Director General Avigdor Kaplan Photo: Tania Susskind

Prof. Orly Elpeleg, head of the Department of Genetic and Metabolic Diseases at the Hadassah Medical Center, has been awarded the KKL-JNF’s 2013 Samuel and Paula Elkeles Outstanding Scientist in Medicine Prize.

"Every successful research project needs partners,” Prof. Elpeleg noted in receiving the prize, “so I would describe this as our rather than as my research.” She explained: “In the 1980s, there were three categories of children's diseases: infectious diseases, cancerous diseases, and all the rest, which were largely ignored in the textbooks, so I decided to research them. We were looking for disease-infected genes, which was sort of like looking for a specific carp in the ocean. To date, we have discovered 30 such genes, findings that have enabled breakthroughs in treating various children's diseases.”

Prof. Yaakov Naparstek, Executive Deputy Director General of Research and Academics at Hadassah, thanked KKL-JNF and the Elkeles family for awarding the prize. "It is my firm belief that biomedical research should be conducted at medical centers like Hadassah,” he said, “where it is possible to go from the research bench to the patient's bedside, and vice-versa. There are those who think that doctors who are also research scientists are a dying breed, but at Hadassah Hospital, we feel that this is critical to the future of medical research. Dr. Elpeleg's success proves just how important this is."

Read more at kkl.org

Hadassah Academic College (HAC) is dedicated to setting minds soaring and preparing young men and women for gratifying careers. The College is committed to playing a vital role in sustaining Israel's economy by helping to fill the need for superbly trained, highly motivated professionals and entrepreneurs.

DONATE

Join

Advocate

Lead

LEARN MORE

View all of our Impact Areas

Date: 12/2/2013

FDA Grants Approval for US Clinical Trials of Hadassah-Developed Technology to Treat Fatty Liver Disease

Hadassah Physicians Receive Prestigious Grants and Awards

New Research at Hadassah: Computational Tools Unravel the Mystery of Transient Amnesia

From Life-Threatening Brain Bleed to Birth of a Daughter

Cookbook Author, Rabbi Marks, Spends Last Days at Hadassah's Hospice

Hadassah’s Revolutionary Tipat Halav Clinics of 1920s Featured in Jerusalem Old City Museum

Victims of Terror Share Their Stories of Anguish and Appreciation with Hadassah President

Hadassah’s Advanced Gene Sequencing Changes the Life of a Family from Uzbekistan

IDF Medic Heroically Battles Terrorist, Both Treated at Hadassah

Orthopedic Trauma Turns Tragedy into Innovation at Hadassah

On the Cutting-Edge of Melanoma Treatment: Hadassah’s Protocols and Research

Saving a Newborn from a Life Without Sight

Terrorist and Victim Sent to Hadassah's Hospitals After Third Attack in Two Weeks

Three Sent to Hadassah After Second Jerusalem Terror Attack of the Week

Clinical Trial of Hadassah-Developed Stem Cell Treatment for Macular Degeneration Gets Go-Ahead from FDA

“We Don’t Say ‘No’,” Hadassah Neurosurgeon Explains in Operating on 82-Year-Old Patient

Cutting-Edge Medicine and Research; a Role Model for Peace: A Briefing from the Hospital's Director General

4 Ways Hadassah Hospital is Preparing for Ebola—Just in Case

Hailing from 17 Countries: the 39th Graduation Class of Hadassah’s International Master of Public Health Program

At Hadassah, Four Recover, Two Tragically Perish After Light Rail Attack



More hMedicine Stories




Hadasit, Hadassah’s Technology Transfer Arm, Reviews 2012’s Accomplishments

When the Hadassah University Medical Center’s physicians suggest a solution to a medical problem which can lead to the development of a new medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its feasibility and supports the promotion of those viable ideas with innovation potential. Although 2012 has been “a year full of challenges for the life science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer, Hadasit still signed 125 agreements for clinical trials, all to be done at Hadassah. In addition, Hadasit signed 15 agreements for cooperation and commercialization of technologies that were developed at Hadassah. Click here to read the latest Newsletter from Hadasit >>

   |  Who We Are  |  What We Do  |  Where We Do It  |  Read About It  |  Join Now  |  Donate  |
  |  Login  |  Contact Us  |  Careers  |  Terms & Conditions  |  
Copyright ©2014 Hadassah is a registered trademark of Hadassah, the Women's Zionist Organization of America